Coherus Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Coherus Oncology, Inc. (CHRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.86 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-09
- Coherus Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.86, a 42.28% decline from fiscal 2024.
- Coherus Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.49.
- Coherus Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $7.04, a 28.16% decline from fiscal 2021.
- Coherus Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $9.80, a 10.42% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | $0.86 10-K · filed 2026-03-09 |
| 2024-12-31 | $1.49 10-K · filed 2026-03-09 |
| 2023-12-31 | $4.19 8-K · filed 2025-11-13 |
| 2022-12-31 | $7.04 10-K · filed 2025-03-17 |
| 2021-12-31 | $9.80 10-K · filed 2022-02-23 |
| 2020-12-31 | $10.94 10-K · filed 2022-02-23 |
| 2019-12-31 | $9.52 10-K · filed 2022-02-23 |
| 2018-12-31 | $7.77 10-K · filed 2021-02-25 |
| 2017-12-31 | $11.70 10-K · filed 2020-02-27 |
| 2016-12-31 | $13.32 10-K · filed 2019-02-28 |
| 2015-12-31 | $18.42 10-K · filed 2018-03-08 |
| 2014-12-31 | $6.65 10-K · filed 2017-03-14 |
| 2013-12-31 | $1.88 10-K · filed 2016-02-29 |
| 2012-12-31 | $1.73 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |